Jane Street’s Zevra Therapeutics ZVRA Stock Holding History

Jane Street’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$534K	Buy	57,300 +34,000	+146%	+$306K	﹤0.01%	7898
2025 Q4	$209K	Buy	23,300 +1,900	+9%	+$18K	﹤0.01%	9635
2025 Q3	$204K	Sell	21,400 -12,800	-37%	-$128K	﹤0.01%	9657
2025 Q2	$301K	Buy	34,200 +16,200	+90%	+$131K	﹤0.01%	7857
2025 Q1	$135K	Buy	+18,000	New	+$143K	﹤0.01%	8674
2021 Q4	–	Sell	-10,600	Closed	-$99K	–	10918
2021 Q3	$99K	Sell	10,600 -15,200	-59%	-$153K	﹤0.01%	9303
2021 Q2	$331K	Sell	25,800 -64,000	-71%	-$688K	﹤0.01%	7978
2021 Q1	$826K	Buy	+89,800	New	+$784K	﹤0.01%	5832

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Jane Street's ZVRA Position: Q1 2026 in Review

Jane Street reduced its Zevra Therapeutics (ZVRA) stake by 61% in Q1 2026, selling an estimated $3.09M and leaving 221,058 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #5031.

Jane Street first reported a position in ZVRA in Q1 2020 and has held it in 14 quarters since. The position peaked at $5.05M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Jane Street held 221,058 shares of Zevra Therapeutics worth $2.06M as of Q1 2026.
Jane Street sold 342,848 Zevra Therapeutics shares in Q1 2026, an estimated $3.09M.
Zevra Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5031 holding.
Jane Street first reported a position in Zevra Therapeutics in Q1 2020 and has held it in 14 quarters since.
Jane Street's Zevra Therapeutics position peaked at $5.05M in Q4 2025.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.